ImmunicIMUX
Recorded

Immunic Stifel 2026 Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration27 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Paul MatteisManaging Director and Head of Biotech Research

All right. Thanks very much, everybody. Happy to be moderating this chat here with the Immunic management team. With me is Erik Lundgren and Jason Tardio. These guys have a somewhat important clinical readout coming up, maybe. We will see. But yeah, with that, just to be more serious, maybe I will have you two guys each just, if you want to say any prepared remarks around the setup for the company going into the end of the year with these two RMS readouts, and then we can dig more into vidofludimus calcium.

Erik LundgrenCEO

Absolutely. Thanks for having us. Thanks for your interest. I am Erik Lundgren, the CEO of Immunic. As Paul indicated, we have a couple very exciting weeks ahead of us. We have two phase III pivotal trials reading out in relapsing MS, the ENSURE-1 and ENSURE-2 studies. Those will be reading out in December, and they would be, assuming they are positive, they would be NDA filing-enabling. We are very focused on that. In addition, we are initiating a third phase III study. This one would be in progressive MS. That is called the ProTEct-MS study, getting that off the ground as well. So, we are looking at some very exciting near-term catalysts, preparing for NDA filing, and doing the commercial build to get ready.

Paul MatteisManaging Director and Head of Biotech Research

Great. Yeah. Well, okay, maybe we will get right into it. You have these two RMS readouts coming up. Maybe just talk about the setup there. You got these two studies. What are you guys going to disclose in the top line, and what sort of target product profile are you hoping to reaffirm?

Erik LundgrenCEO

Yeah. I would start with what do we see as the big unmet needs in MS, and I think there are many, but I would draw your attention to two. The first one is really around progression. There has been a ton of innovation in MS over the last 20 years or so, but progression remains a very, very difficult place to move the needle on, and really the overwhelming unmet need. We think with our lead asset, which is called vidofludimus calcium, it would be the first approvable MS treatment that is neuroprotective in nature. It has two mechanisms. One is on the neuroinflammatory side, and one is on the neurodegenerative side. We think we have got a really interesting and unique shot at moving the needle in ways that other MS therapies have been unable to do on progression. So that is sort of unmet need number one.

Erik LundgrenCEO

The second big unmet need is really around safety and tolerability. There's a lot of medicines approved. It's really hard for patients to stay on them. I think we have demonstrated, out of a pretty robust safety database to date, 3,500 patients, a very, very unique safety and tolerability profile. That's going to matter right away, because there's a lot of need for medicines that people can start and stay on. In particular, there's a large bolus of patients, actively treated MS patients, that are on anti-CD20s today. Anti-CD20s are the dominant sort of class of treatment in relapsing MS, and they're really wonderful medicines, but you can't ablate people's B cells in perpetuity.

Erik LundgrenCEO

You need medicines that folks can come off of anti-CD20s and step onto and still confer disease control, hopefully do something on progression, and do so with a safety and tolerability profile that is consummate to the sort of challenge of treating people who are immunosuppressed.

Paul MatteisManaging Director and Head of Biotech Research

Right. Okay. That's the thesis there, and then as it relates to this phase III study, maybe talk about the phase II data, and what does that data sort of predict for the most likely efficacy and safety profile to come out in pivotal trials?

Erik LundgrenCEO

Yeah. We ran a pretty robust phase II study in relapsing MS called the EMPhASIS study. It gave us three things that gave us a lot of confidence going into this. The first is looking at the MRI outcomes. Gadolinium-enhancing lesions are incredibly strong predictors in the phase II setting of the clinical outcomes in a phase III setting, and we had a very robust 78% reduction in Gadolinium-enhancing lesions in the phase II study. That gives us a tremendous amount of confidence that we not only have an active medicine here, but that it's clinically relevant range for the primary outcome in the phase IIIs. Second is, although they weren't powered, a phase II study wasn't powered for statistical significance on relapses. We did, of course, look at relapses, and we saw a 42% risk reduction in relapse, was the point estimate.

Erik LundgrenCEO

Not significant, obviously, again, but that's a really healthy place to be landing in terms of a read-through on the confidence. Then third is the safety and tolerability, and I'll keep coming back to that because I think it's so meaningful, but the safety and tolerability profile was I've looked at everything in MS for the last dozen years. I've never seen anything quite like this in terms of the safety and tolerability, and I think it's really highly differentiated. It addresses a lot of the limitations of the currently available therapies, and it's going to be pretty appealing to physicians and to patients.

Paul MatteisManaging Director and Head of Biotech Research

Yep. Okay, great. You also talked at the start about disability progression being a significant unmet need, or maybe progression in general. But to that point, what is your expectation and thesis there around some of the secondary endpoints? Maybe you could also talk about the Nurr1 angle, and whether or not that angle is likely to manifest in the RMS data.

Erik LundgrenCEO

Yeah. With RMS studies, I think what's typically done, and we'll do the same, is because the event rate is, you're powering on relapses, and the event rate for progression is less common. So we're going to have these twin studies, same study protocols, so we will look at the progression endpoints in a pooled fashion. So that's a way to get a little bit more signal. But what I would expect, Paul, is I would expect a numerical advantage. I would expect to see consistency across, but I do think in an 18-month relapsing study, the biostats are kind of against a screaming P-value, but we'll see. I mean, we're going to give ourselves the absolute best shot at seeing it. We certainly hope to see it, and if we don't see it, I think it wouldn't cause me to erode my confidence in Nurr1.

Erik LundgrenCEO

I think this is a study that's built to look at relapses and MRI and safety. It's certainly not a set of studies built to look at progression. That's why we're going to run a third study that is built around progression in a progressing population with progression endpoints and powered to do it.

Paul MatteisManaging Director and Head of Biotech Research

What would you define as a home run safety tolerability profile in phase III?

Erik LundgrenCEO

Well, I think I'd look first to, are we able to address the main problems that are out there among what we hear from patients? You want a clean liver signal, so that's one. You want to address infection imbalances, in particular, serious or opportunistic infection imbalances. That would be number two. Then I think you want to look at the day-to-day tolerability issues that are the number one driver of treatment discontinuation amongst the oral treatments that are currently approved in MS. This is nausea, vomiting, diarrhea, flushing, these types of symptoms. So you want to make sure that you're handling those. Then there's another medicine that was approved about 15 years ago called teriflunomide or AUBAGIO, which is a DHODH inhibitor, which we share that targeting mechanistic pathway with. They also have alopecia rates, like, north of 20%.

Erik LundgrenCEO

That's not a fantastic thing to have in a population of people who are two-thirds female, diagnosed around 30 years of age. So, we want to be able to clean up some of those issues as well.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day